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Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to
their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers
have been developed for various applications, including diagnostics, molecular imaging,
biomarker discovery, target validation, therapeutics, and drug delivery. Due to their high
specificity and binding affinity, aptamers directly block or interrupt the functions of target
proteins making them promising therapeutic agents for the treatment of human maladies.
Additionally, aptamers that bind to cell surface proteins are well suited for the targeted
delivery of other therapeutics, such as conjugated small interfering RNAs (siRNA) that
induce RNA interference (RNAi). Thus, aptamer-siRNA chimeras may offer dual-functions,
in which the aptamer inhibits a receptor function, while the siRNA internalizes into the cell
to target a specific mRNA. This review focuses on the current progress and therapeutic
potential of RNA aptamers, including the use of cell-internalizing aptamers as cell-type spe-
cific delivery vehicles for targeted RNAi. In particular, we discuss emerging aptamer-based
therapeutics that provide unique clinical opportunities for the treatment various cancers
and neurological diseases.
Keywords: RNA aptamers, systematic evolution of ligands by exponential enrichment, RNA interference, small
interfering RNA, targeted delivery
INTRODUCTION
Aptamers are oligonucleotides selected in vitro to bind target
molecules with high affinity and specificity due to their stable
three-dimensional shapes. This high affinity is maintained in vivo,
thereby enabling the aptamer to bind a specific receptor or ligand
on the surface of the target cell. Hundreds of aptamers have been
identified for specific functions and molecular targets, providing
an unlimited number of possibilities for future therapeutics (Keefe
et al., 2010).
Aptamers are selected in a process called systematic evolution of
ligands by exponential enrichment (SELEX; Ellington and Szostak,
1990; Tuerk and Gold, 1990). SELEX involves enriching for single-
stranded RNA or DNA sequences based on retention of this
sequence while it is bound to a target of interest (Figure 1). There
are multiple variations of SELEX including cell-based SELEX and
blind SELEX (Thiel et al., 2012). Cell-based SELEX involves select-
ing for aptamers that bind to an expressed protein and ensures
that the aptamer targets the protein in its in vivo conformation.
Blind SELEX selects an aptamer for an unknown target that is only
present or more abundant in a diseased cell, such as an aptamer
that binds to cancer cells but not healthy cells. Typically, the par-
ticular target is determined after the selection occurs. SELEX is an
integral part of aptamer selection and is responsible for the broad
range of targets for aptamer selection.
The function of aptamers is similar to that of current thera-
peutics including antibodies and small molecule therapy. Small
molecules are about the same size or smaller than aptamers,
and thus have comparable systemic clearance (Nimjee et al.,
2005). However, aptamers offer a functional advantage over small
molecule therapy, as aptamers are designed for cell specificity,
thereby decreasing the potential off-target effects and toxicity of
small molecule therapy. Aptamers are also similar to antibodies in
that they tightly bind targets in a specific manner via structural
elements and effect downstream pathways of the target molecule
(Keefe et al., 2010). However, aptamers offer important advantages
over their protein counterparts. The aptamer selection process is
generally faster than monoclonal antibody selection and allows
optimization of binding affinity by successive rounds of evolu-
tion and screening. While antibodies often elicit strong immune
responses resulting in a loss of efficacy, immunogenicity is limited
by aptamers due to chemical modifications on the aptamers. Due
to their small size, aptamers have improved transport and tissue
penetration than antibodies. Finally, in contrast to polyclonal anti-
bodies, which must be selected in vivo resulting in a heterogeneous
population, aptamers are synthesized in vitro as a homogenous
population. As a result, production of aptamers offers greater
quality control and lower expense compared to antibodies.
While RNA is notoriously prone to instability and degrada-
tion, chemical base modifications improve the stability of RNA
aptamers (Mayer, 2009). Without chemical modification, the RNA
aptamers will degrade and no longer bind or recognize tar-
gets. Modifications prevent RNase A mediated single-stranded
RNA cleavage. Aptamers often have single-stranded loops that are
responsible for target recognition. Therefore, the modifications
keep hairpin loops and other single-stranded structures intact to
maintain the binding affinity of the aptamer. Due to the increased
resistance to RNases, aptamers are stable for over 2 h in human
serum (Lorger et al., 2003). In addition to blocking RNase cleav-
age, modifications also increase the thermodynamic stability of
aptamers. An increase in stability enhances the binding affinity
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FIGURE 1 |The SELEX process. An initial DNA library is transcribed into RNA and the aptamers that bind to cells or beads with no target protein are eliminated.
The remaining aptamers are applied to cells or beads with target protein and the bound aptamers are retrieved, amplified, and the SELEX process repeats.
of the aptamer to its target by ensuring the aptamer retains con-
formation. Incorporation of modified bases occurs by replacing
pyrimidines with modified pyrimidines during in vitro transcrip-
tion. Modifications include addition of fluorine (Fluoropyrimi-
dine or F-Py),O-methyl (OMe) or amino group to the 2′ position
of deoxyribose, which makes DNA bases appear as RNA bases for
enhanced stability (Kawasaki et al., 1993).
APTAMERS AS THERAPEUTICS
Aptamers have shown early promise as therapeutics, as dozens of
aptamers are in pre-clinical studies and at least nine have reached
clinical testing (Ni et al., 2011a). Therapeutic strategies typically
involve binding of the aptamer directly to a therapeutic target to
modulate downstream signaling. Aptamer-based therapeutics for
cancer include those that target adherence factors, immune system
modulators, receptor tyrosine kinases (RTKs), and modulators of
cell growth. Using the information gained from developing thera-
peutic aptamers for cancer, several aptamers have been developed
to treat or identify neurological diseases. These include multi-
ple sclerosis (MS), stroke, Alzheimer’s disease (AD), Parkinson’s
disease (PD), variant Creutzfeldt–Jakob’s disease (vCJD), and neu-
ronal cell death. In addition to therapeutic value as single agents,
aptamers also provide a new strategy for the delivery of oligonu-
cleotides and small molecules in a cell-specific manner. Aptamers
are amenable to conjugation with other therapeutic nucleic acids
or small molecules by covalent or non-covalent linkage. Indeed,
this property has been utilized for a variety of chimeric molecules
that contain an aptamer-conjugated with a small interfering RNA
(siRNA) or short hairpin RNA (shRNA) that induce targeted RNA
interference (RNAi). Effective knockdown is then observed upon
treatment. To enhance the delivery of aptamer-siRNA chimeras,
additional nanocarriers may be added to the complexes. The deliv-
ery and therapeutic utility of aptamers will be discussed in this
article for in vitro and in vivo applications. The use of aptamers for
the treatment of cancer and neurological diseases will be discussed
in this section.
CANCER
Therapeutic aptamers that engage with a specific target molecule
on the surface of the cell can modulate downstream signaling
pathways. Aptamers typically inhibit such signaling by preventing
structural changes in the target molecule, inhibiting dimerization
to associated molecules, or phosphorylation of downstream pro-
teins (Esposito et al., 2011; Roth et al., 2012). Due to these and
other properties, treatment of cancer is one of the leading uses for
aptamers. Learning from research on the development of aptamers
for cancer treatment, several groups are working on develop-
ing aptamers for the identification and treatment of neurological
diseases.
Aptamers that are designed to distinguish between healthy and
tumorigenic cells are especially useful for the detection and treat-
ment of cancer. Cancer-targeting aptamers can be used for the
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selective treatment and elimination of only tumorigenic cells.
Such specificity is needed for cancer treatment, as many current
chemotherapeutics present side effects such as massive amounts of
cell death and depletion of immune cells to fight infection (Bunka
and Stockley, 2006; Burnett and Rossi, 2012). Hence, aptamer-
mediated therapies are designed to minimize these adverse effects
by not targeting non-tumorigenic cells and helping to maintain
homeostasis in the patient. These aptamers treat various aspects
of tumorigenesis, which will be discussed below (Table 1).
ADHESION
Metastasis may be prevented with aptamers that inhibit the for-
mation of tumors at secondary sites. Several genes in the selectin
family are highly overexpressed on cancer cells and promote can-
cer cell adherence to endothelial cells to form tumors at secondary
sites (Nimjee et al., 2005). RNA aptamers to E-selectin and X,
a carbohydrate responsible for adhering leukocytes to endothe-
lial cells by interacting with selectins, have been selected for to
inhibit cancer cell adherence (Jeong et al., 2001; Nimjee et al.,
2005; Mann et al., 2011). The E-selectin aptamer blocks the inter-
action of E-selectin with ligands expressed by endothelial cells and
decreases the adherence of cancer cells to endothelial cells (Mann
et al., 2010, 2011) _ENREF_9. Sialyl-Lewis X aptamer works in
a similar manner, by preventing the adherence of cancer cells to
the endothelium. Sialyl-Lewis X is the preferred ligand for the
selectins during attachment, so this aptamer prevents adherence
to both P-selectin and E-selectin. Both aptamers prevent adhesion
in cell culture thus far, but have not been tested in vivo.
Immune system manipulation
Modulation of the immune system is another important hallmark
of tumorigenesis. Tumor cells inactivate the immune system to
prevent tumor clearance. Aptamer inhibition of cytotoxic T-cell
antigen 4 (CTLA-4) is one approach to prevent immune system
inactivation and promote tumor elimination. CTLA-4 acts as an
“off” switch for T-cell proliferation and therefore attenuates T-
cell mediated immune responses (Santulli-Marotto et al., 2003).
Anti-CTLA-4 aptamer promotes T-cell expansion and anti-tumor
immunity in mice, as well as increasing the susceptibility of weakly
immunogenic tumors to chemotherapy. It also can be used a tumor
vaccine adjuvant by concurrent delivery of tumor antigen with
aptamer to dendritic cells. As with antibodies, this aptamer can be
used in a tetrameric form to enhance anti-tumor effects.
Another approach for enforcing the immune system against
tumors is to inhibit the activity of tumor-associated macrophages
(TAMs) and myeloid derived suppressor cells (MDSCs). Through
activation of the IL-4Rα signaling pathway, these cells increase
angiogenesis, promote tumor cell invasion, and inhibit anti-tumor
immunotherapy. The IL-4Rα signaling cascade results in cell
growth mediated by the activation of STAT1 and STAT6, which
induces anti-apoptotic activity (Roth et al., 2012). Anti-IL-4Rα
aptamer binding leads to depletion of MDSCs and TAMs, which
inhibited tumor progression and size in mice.
Noxxon Pharma AG has developed an l-RNA (Spiegelmer)
aptamer (NOX-A12) that binds to the chemokine (C-X-C motif)
ligand 12 (CXCL12; Darisipudi et al., 2011), a ligand involved
in tumor metastasis, cell homing, and angiogenesis (Keefe et al.,
2010). NOX-A12 is a 45-nt l-RNA aptamer with a 3′-terminal
PEG linkage (Sayyed et al., 2009). This therapeutic has been
tested in two Phase I clinical trials to assess its safety and
tolerability (NCT00976378 and NCT01194934). Currently, two
Phase II clinical trials are scheduled for NOX-A12 for the treat-
ment of lymphoma and multiple myeloma (NCT01521533 and
NCT01486797).
Receptor tyrosine kinase
In addition to preventing metastasis, inhibition of tumor growth
is important for the treatment of cancer. RTKs are cell sur-
face receptors that are responsible for the regulation of key cell
processes. Unregulated RTKs are often associated with tumor
growth. Current clinically approved antibody therapies success-
fully target RTKs (Scott et al., 2012). Cetuximab targets endothelial
growth factor receptor (EGFR), and Bevacizumab targets vascular
endothelial growth factor (VEGF). Four aptamers have also been
developed that prevent the growth of tumors by inhibiting RTKs:
anti-HER3, anti-RET, anti-EGFR, and anti-VEGF (Huang et al.,
2001; Chen et al., 2003; Cerchia et al., 2005; Esposito et al., 2011).
The RTK HER3 is responsible for increased drug resistance in
HER2+ breast cancer (Chen et al., 2003). An aptamer-targeting
HER3 inhibits stimulation of cell growth by the growth factor
Table 1 |Therapeutic RNA aptamers for treatment of cancer.
Aptamer target Selection method Model Reference
E-selectin Recombinant protein followed by cell-based SELEX Cell culture Mann et al. (2010, 2011)
Siacyl Lewis X Siacyl Lewis X conjugated to agarose beads Cell culture Jeong et al. (2001)
CTLA-4 CTLA-4 antibody protein SELEX Mouse model Santulli-Marotto et al. (2003)
IL-4Rα Magnetic epoxy beads attached to protein Mouse model Roth et al. (2012)
NOX-A12 Protein SELEX Phase II clinical trial Darisipudi et al. (2011)
HER3 Protein SELEX (rounds 1–8), isolation of band from
gel shift (rounds 9–15)
Cell culture Chen et al. (2003)
RET Cell-based SELEX Cell culture Cerchia et al. (2005)
EGFR Cell-based or protein-based (respectively) Cell culture Esposito et al. (2011), Li et al. (2011)
VEGF Protein bound to beads Mice-tumors FDA
approved for human AMD
Bell et al. (1999), Huang et al. (2001)
Alpha-fetoprotein (AFP) Protein bound to beads Cell culture Lee and Lee (2012)
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heregulin and prevents signaling through the HER3 receptor. Thus
far, this aptamer has been tested in vitro and inhibits heregulin-
induced proliferation of MCF7 cells. Since this aptamer is specific
for HER3 signaling, it may therapeutically provide a safe alter-
native to currently used anti-cancer drugs such as tamoxifen or
trastuzumab (Davies and Hiscox, 2011).
Anti-RET aptamer exhibits anti-cancer activity in cell culture
by binding to the human receptor tyrosine kinase, RET (Cerchia
et al., 2005). Mutated RET is an oncogene that upon dimeriza-
tion causes thyroid carcinomas to develop by phosphorylating
transcription factors involved in cell growth such as ERK, NF-κB,
and AKT. Inhibition of RET dimerization prevents the phospho-
rylation of transcription factors involved in the proliferation of
tumor cells. In vivo mouse studies of this aptamer are necessary
to further demonstrate its efficacy and assess potential off-target
effects.
Tumor cells over expressing the RTK EGFR are associated
with poor prognosis due to phosphorylation-induced activation
of AKT, STAT, and ERK pathways and to tumor cell prolifera-
tion, resistance to apoptosis, and metastasis (Esposito et al., 2011;
Li et al., 2011). Anti-EGFR aptamers bind to EGFR monomers
and heterodimers composed of EGFR and an additional RTK on
the cell surface in cell culture (Li et al., 2011). This inhibits the
activation of the downstream transcription factors that lead to
increased tumorigenesis (Esposito et al., 2011). These aptamers
also inhibit tumor growth in mice and induce apoptosis of tumor
cells resistant to current antibody and chemical based anti-EGFR
treatment, likely due to the aptamers small size and the inhibition
of multiple forms of EGFR present on cell surfaces (Esposito et al.,
2011).
Vascular endothelial growth factor is the ligand for VEGFA and
VEGFB, both of which are RTKs that cause increased vascular-
ization of blood vessels. An aptamer against VEGF has been used
to treat pediatric Wilm’s tumors in mice by reducing tumor vas-
cularization (Huang et al., 2001). Similar to VEGF antibody, the
aptamer suppressed over 80% of tumor growth after 6 weeks, how-
ever, the aptamer is smaller and therefore may cause less off-target
effects and toxicity compared to an antibody. This is critical for
pediatric patient because off-target effects may prevent the growth
of their developing blood vessels. VEGF165 is the epitope targeted
by this aptamer, which is the same epitope that is targeted by an
aptamer clinically approved for age-related macular degeneration
(AMD) called Pegaptanib (Vinores, 2006; Tolentino, 2011). Pegap-
tanib effectively treats AMD by halting blood vessel growth in the
eye, preventing blindness.
Cell expansion
Hepatocellular carcinoma is often associated with production of
alpha-fetoprotein (AFP). AFP is associated with liver cancer devel-
opment due to cell growth and differentiation of hepatic cells.
Interaction of AFP with an AFP receptor results in the stimu-
lation of oncogenic mRNA production. As a result, an aptamer
has been developed that binds to AFP, reduces cell viability, and
reduces downstream oncogene expression in cell culture (Lee and
Lee, 2012). This aptamer may eventually be used for the treatment
and analysis of hepatocellular carcinoma.
NEUROLOGICAL DISEASE
Diseases of the nervous system are difficult to identify and treat
because it is difficult to access the nervous system (Lindvall and
Kokaia, 2006). Once identified by brain biopsy or some other
method, treatment options are scarce. Aptamers provide viable
options for treatment: small size allows for deep tissue penetra-
tion and crossing of the blood brain barrier, high affinity reduces
the amount of aptamer needed for treatment and reduces the
likelihood of side effects, and easy regulatory mechanisms adds a
fail-safe to the treatment (de Franciscis et al., 2009). Many of the
therapies discussed in this section are similar to strategies used for
the treatment of cancer. Regulation of the immune system is often
important for treating neurological disorders, while mobilization
of the immune system is critical for cancer treatment. Aptamers
have been developed for treatment of several conditions targeting
MS, stroke, AD, prions, and other proteins (Table 2).
Multiple sclerosis
Multiple sclerosis is an incurable disease caused by inflamma-
tion of the CNS identified by leukocyte infiltration in the CNS.
Treatment options available merely modify the disease progres-
sion or treat the symptoms present. Experimental autoimmune
encephalitis (EAE) is an animal disease that closely resembles MS
Table 2 |Therapeutic RNA aptamers for treatment of neurological disease.
Aptamer Selection method Application Model Reference
IL-17 Protein bound to beads MS Mouse Ishiguro et al. (2011)
Midkine Protein bound to beads MS Mouse Muramatsu (2011)
Factor IXa Protein bound to nitrocellulose Stroke Mouse-stroke Humans-phase
II clinical trial for acute
coronary syndrome
Rusconi et al. (2002)
BACE1 Protein bound to sepharose beads Alzheimer’s In vitro Rentmeister et al. (2006)
Aβ Protein bound to sepharose beads Alzheimer’s In vitro Ylera et al. (2002)
Prion protein (PrP) Protein bound to nitrocellulose vCJD In vitro Murakami et al. (2008)
AMPA Membrane bound protein Stroke, Parkinson’s, treat
neuronal cell death
In vitro Park et al. (2011)
Nogo-66 Protein bound cellulose Promote myelin sheath
regeneration, neuronal growth
Cell culture Wang et al. (2010)
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and serves as a mouse model to study MS disease progression
and therapies. Since the cause of MS has not been determined,
aptamers play a role in determining the biology of EAE and MS in
addition to providing new treatment options. Two such aptamers
are the IL-17 aptamer and the midkine aptamer. IL-17 aptamer
inhibits the proinflammatory activity of IL-17, reducing the neu-
rological symptoms observed in the EAE mouse model (Ishiguro
et al., 2011). Another aptamer against midkine may be useful for
the treatment of MS because the aptamer reduced inflammation
observed in mouse EAE (Wang et al., 2008b; Muramatsu, 2011).
Midkine promotes neuronal and tumor cell growth in addition
to inhibiting regulatory T-cell expansion. MS is characterized by
a lack of T-cell regulation, so midkine repression may reduce the
neuroinflammation by inducing regulatory T-cells to control the
immune system.
Stroke
Ischemic strokes occur when blood flow to the brain ceases usually
because of a blood clot in the brain or other part of blood vascula-
ture (Blake et al., 2011). Inflammation and lack of blood flow from
the ischemic stroke often lead to permanent brain damage. Tissue
plasminogen activator (TPA) is the only approved treatment for
stroke that acts by dissolving blood clots allowing normal blood
flow to resume, however, TPA is recommended to be given within
4.5 h of stroke onset (Demers et al., 2012). This restricts the num-
ber of patients able to receive TPA, which is further restricted
because TPA treatment also can cause hemorrhaging. Due to this
complication, there is a need for better therapy with a mecha-
nism for inactivating the therapeutic to prevent hemorrhaging. An
aptamer candidate with similar activity to TPA is the Factor IXa
aptamer, RB006, which Regado Biosciences currently has Phase II
clinical trials for use in acute coronary syndrome (NCT00932100
and NCT00113997; Blake et al., 2011; Burnett and Rossi, 2012).
Factor IXa is a clotting factor, so inhibition by an aptamer dissolves
blood clots in addition to reducing inflammation and improv-
ing neurological function in mice. To prevent hemorrhaging, a
mechanism for inactivating the aptamer is available using aptamer
antidote RB007. This aptamer antidote binds and inactivates the
Factor IXa aptamer, therefore allowing Factor IXa levels to return
to normal. As a stroke treatment, this presents a safe, regulated
alternative to TPA.
Alzheimer’s disease
While the particular causes AD remain unknown, the deposition
of β-amyloid (Aβ) protein seems to disrupt the functional con-
nectivity of neurons in healthy areas of the brain (Bero et al.,
2012). Aβ also causes synuclein accumulation in the brain and
PD (Masliah et al., 2001). Diagnosis occurs by a brain biopsy for
AD, and no treatment for AD or PD is available mostly due to a
lack of information about the diseases. Since few targets exist for
AD or PD, a biomarker assay using SOMAmers has been devel-
oped (Baird et al., 2012). SOMAmers are aptamers with different
functional groups on uracil residues that enhance the stability and
functionality of the aptamer. This assay was developed to test age-
related differences in proteins found in the cerebrospinal fluid.
The authors identified over 200 biomarkers of aging which may
be used to help diagnose and eventually treat AD or PD.
An aptamer that targets the β-secretase (BACE1) protein is
designed to inhibit the formation of Aβ for treatment of AD
(Rentmeister et al., 2006). Aβ is created by the cleavage of β-
amyloid precursor protein by BACE1. The anti-BACE1 aptamer
may help to elucidate the cause of AD and provide new treatment
options, but still must undergo further testing in culture or ani-
mal models. Two different aptamers against Aβ present another
possible therapeutic for the treatment of AD. The goal of the first
aptamer was to select an aptamer that bound to the multimeric
Aβ, but did not recognize monomeric Aβ (Ylera et al., 2002). This
aptamer was successful for the marking of Aβ fibrils and in the
future, may be used for the diagnosis or treatment of AD. A second
aptamer was developed that also recognized Aβ fibrils and other
amyloid proteins in vitro (Rahimi et al., 2009; Rahimi and Bitan,
2010). This aptamer does not recognize monomeric or oligomeric
Aβ even though the aptamer was selected against multimeric Aβ.
Nevertheless, this aptamer may serve as an improved diagnostic
tool than current assays due to increased aptamer sensitivity for
AD fibrils.
Variant Creutzfeldt–Jakob disease
Although distinct from classic Creutzfeldt–Jakob disease (CJD),
vCJD is thought to be closely related to mad cow disease and is
caused by deposition of an insoluble form of prion protein (PrP)
in the brain (Murakami et al., 2008). It is currently unknown
what causes the structural change from the soluble form to the
insoluble, infectious form. PrP binds to nucleic acids making it
difficult to obtain a functional aptamer, yet several aptamers have
been developed (Proske et al., 2002; Rhie et al., 2003; Murakami
et al., 2008). Two aptamers may serve as therapeutics for vCJD
due to their recognition of insoluble PrP over soluble PrP in vitro.
The aptamers also prevented the formation of insoluble, infectious
PrP. A third aptamer recognizes bovine PrP and was developed
to detect PrP in bovine brain homogenate with possible appli-
cation in humans (Murakami et al., 2008). This aptamer may
play a role in preventing PrP contaminated beef from reach-
ing the food supply. The other two aptamers have the possi-
bility for therapeutic use in humans and the prevention of PrP
formation.
Broad effectors
Neuron cell death due to uptake of too much Ca2+ through
the glutamate ion channel, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor, is the cause of many
neurological diseases (Dingledine et al., 1999; Huang et al., 2009;
Park et al., 2011). AMPA receptor is responsible for fast synaptic
transmission in the CNS and is composed of multiple subunits.
Aptamer targets the closed conformation of the GluA2 subunit
of the AMPA receptor, which may regulate Ca2+ flow, but has
not been tested in cell culture. Aptamers to GluA2 have potential
for therapeutic use in treating stroke, PD, and other diseases hall-
marked by neuron death. These aptamers allow for tight control of
the AMPA receptor and may be therapeutically valuable for many
neurological diseases characterized by abnormal AMPA activity.
Another important process in reversing the effects of neu-
rodegenerative disease is generating new neurons, which can be
accomplished by the regeneration of myelin sheath that coats
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axons within the central and peripheral nervous systems (Wang
et al., 2010). Inhibition neuron growth and regeneration occurs
via Nogo-66 (NgR) receptor association with p75 leading to the
activation of RhoA, an inhibitor of myelin sheath regeneration
and axon elongation (Yamashita and Tohyama, 2003). Anti-NgR
aptamer binds with high affinity to NgR, prevents the association
of NgR with p75, and competes with agonists of NgR/p75 associ-
ation (Wang et al., 2010). Growth of axons in neurite outgrowth
assays also occurs upon treatment with aptamer.
RNA APTAMER-MEDIATED TARGETED THERAPY
By binding and blocking enzyme activities or protein–protein
interaction, aptamers alone show the promise as new class of
therapeutic agents in the treatment human maladies (Nimjee
et al., 2005; Bunka and Stockley, 2006; Keefe et al., 2010). In
addition, cell-specific aptamers that actively target a distinct cell
population or tissue also show the potential in therapeutic tar-
geting or delivery (Syed and Pervaiz, 2010; Zhou and Rossi, 2010,
2011). For instance, cell-specific aptamers may be functionalized
with other therapeutic agents or delivery vehicles, such as siRNA,
shRNA, microRNA (miRNA), toxins, enzymes, chemotherapy
agents, photodynamic molecules, radionuclides, and nanocarri-
ers. Such design for the aptamer-mediated targeted therapy may
enhance therapeutic index as well as attenuate the overall toxicity
of the drugs (Dua et al., 2011; Tan et al., 2011).
In present, an increasing number of cell-specific RNA aptamers
have been successfully adopted for targeting delivery of various
cargoes in vitro as well as in vivo. The cell-specific RNA aptamers
used as delivery ligands or vehicles for various cargoes in can-
cer therapy are summarized in Table 3. Different strategies have
been employed to functionalize RNA aptamer to the cargoes or
carriers. For example, due to the nucleic acid nature of the RNAi
therapeutics, siRNA, or shRNA molecules can be directly fused to
a RNA aptamer backbone to achieve a chimeric RNA for the deliv-
ery purpose (Zhou and Rossi, 2010). Alternatively, aptamer and
therapeutics also can be non-covalently assembled via an adapter
linkage. In addition, aptamers can be chemically synthesized with
specific functional groups on 5′- or 3′-termini for conjugation
with other therapeutics or drug-loaded nanocarriers. The follow-
ing sections mainly discuss current promising pre-clinical studies
where cell-specific RNA aptamers have been utilized for targeted
RNAi. Several representative examples of aptamer-mediated RNAi
are highlighted below.
APTAMER-MEDIATED siRNA/shRNA DELIVERY
As mentioned above, aptamer-mediated specific recognition relies
essentially on their unique 3D structure to their targets (Mayer,
2009). Other types non-coding RNA, such as siRNA or small hair-
pin (sh)RNA, function by specific sequence complementarity to
target mRNA (Fire et al., 1998; Elbashir et al., 2001). However, the
efficient and safe delivery of RNAi-based therapeutics into specific
tissue or cell populations is still the principal challenge in the clin-
ical development of RNAi (Whitehead et al., 2009; Higuchi et al.,
2010; Davidson and McCray, 2011). By combining the two thera-
peutic non-coding nucleic acids into a single chimeric molecule,
the resulting targeted RNAi therapeutics could further enhance
therapeutic potency.
Non-covalent aptamer-siRNA conjugates
To date, the most established and best characterized cell-specific
RNA aptamers for targeted therapy are the 2′-fluoro modified anti-
PSMA aptamers with low nanomolar affinity binding constants
(Lupold et al., 2002). PSMA, a transmembrane protein, is highly
expressed in human prostate cancer and the vascular endothelium
and is continually recycled from the plasma membrane (Liu et al.,
1998; Tasch et al., 2001). The parental anti-PSMA aptamers (A9
and A10) and its truncated versions (A10-3 and A10-3.2) have
been successfully employed for specifically delivery of siRNAs or
shRNAs in vitro and in vivo animal model (Table 3).
A proof of concept study by Ellington et al. (Chu et al.,
2006a) validated the aptamer-mediated target delivery technology
using the A9 anti-PSMA aptamer. Two biotinylated A9 anti-PSMA
aptamers and two biotinylated 27-mer Dicer substitute siRNAs
(DsiRNAs) against lamin A/C or GAPDH were non-covalently
assembled on a streptavidin bridge through biotin-streptavidin
interaction (Figure 2A). When the resulting multivalent conju-
gates were incubated with PSMA-positive LNCaP cells or the
control PC-3 cells, selective cellular uptake and specific RNAi activ-
ity was observed in LNCaP cells, suggesting targeting specificity
mediated by aptamer-siRNA conjugates.
Covalent aptamer-siRNA or shRNA chimeras
A different strategy was used to develop a covalent aptamer-siRNA
chimera using the A10 anti-PSMA aptamer (McNamara et al.,
2006). In this approach, a 2′-fluoro modified PSMA aptamer was
directly fused with the passenger strand of a 21-mer siRNA duplex,
which subsequently was annealed with its complementary guide
strand (Figure 2B). The resulting A10 aptamer-PLK1 or BCL2
siRNA chimeras induced specific silencing of target genes and
cell death in prostate cancer cells expressing PSMA. Addition-
ally, in an athymic mouse model the intratumoral injection of the
aptamer-siRNA chimeras allowed effective gene down-regulation
and tumor regression.
The anti-PSMA aptamer-siRNA has undergone further opti-
mization to improve the in vivo therapeutic potency and circu-
lating half-life of the anti-PSMA aptamer-siRNA chimera (Dassie
et al., 2009). By rational design of the aptamer and siRNA, the same
group optimized the previous A10 aptamer-PLK1 siRNA chimera
for systemic administration by implementing three important fea-
tures. First, the aptamer portion was truncated from 71 (A10
aptamer) to 39 nucleotides (A10-3.2) which still preserves orig-
inal specificity and affinity to PSMA, thus allowing a large-scale
solid-phase synthesis of the chimeras. Second, a 2-nt overhang
was added at the 3′-end of guide strand of siRNA portion or
the guide and passenger strands of siRNA portion were swapped
to append to the aptamer portion to facilitates Dicer access,
processing and loading, thus improving RNAi activity by about
100-fold. Third, the 5′-end of the passenger strand of siRNA por-
tion was conjugated with a 20-kDa polyethylene glycol (PEG)
linkage, which increases the molecular weight and improves its
pharmacokinetic profile. Systemic administration of the opti-
mized aptamer-siRNA chimera, termed swap-2′F-PEG chimera, in
immune-compromised mice bearing PSMA-expressing prostate
tumors yielded increased circulating half-life (from <35 min to
>30 h) and bio-availability. Moreover, the swap-2′F-PEG chimera
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FIGURE 2 | RNA aptamer-mediated targeted RNAi delivery in cancer
therapy. (A) Schematic of non-covalent aptamer-siRNA conjugates.
Cell-specific aptamers and 27-mer Dicer substrate siRNA duplexes were
chemically conjugated with a biotin group. Thus, two biotinylated DsiRNAs
and two aptamers were non-covalently assembled via a Streptavidin
platform. (B) Schematic of covalent aptamer-siRNA or shRNA chimeras.
The 2′-Fluoro modified aptamer and siRNA sense strand were
co-transcribed, followed by annealing of the complementary siRNA
antisense strand to complete the chimeric molecule. Or the aptamer and
shRNA strand were co-transcribed to obtain the 2′-Fluoro modified
chimeric RNA. (C) Schematic of non-covalent aptamer-nanocarrier
conjugates. A nanocomplex was formulated by incorporating siRNAs and
aptamers onto polyethyleneimine (PEI)-citrate nanocarriers via
electrostatic interaction. Or the siRNAs with SH group were absorbed on
PEI-coated quantum dot nanoparticles via non-covalent electrostatic
interaction. And then aptamers with a single thiol group were coupled to
siRNAs via thiol-disulfide exchange reaction to form aptamer-siRNA
chimeras. (D) Schematic of covalent of aptamer-nanoparticle conjugates. A
5′-NH2-modified aptamer was chemically synthesized and covalently
decorated on the surface of a polymer composed of branched
polyethyleneimine grafted with polyethylene glycol (PEI-PEG) for
co-delivery of shRNA and chemotherapy agents.
provided prolonged silencing and pronounced tumor regression
at significantly lower dosage (5× 0.25 nmol pre-injection) than
an earlier version of the chimera lacking PEG (swap-2′F chimera),
which reduces the risk of harmful side effects and the treatment
costs.
Since the introduction of the simple covalent aptamer-siRNA
chimera, several different groups have fused various siRNAs to the
A10 anti-PSMA aptamer and its truncated versions for siRNA or
shRNA delivery. Wullner et al. (2008) designed two bivalent anti-
PSMA aptamer-EEF2 siRNA chimeras, in which the siRNA por-
tion serviced either as a spacer joining the two A10-3 anti-PSMA
aptamers or as a shRNA format to be tethered to the 3′ end of one of
the aptamer dimers. The incubation with PSMA-positive prostate
cancer cell resulted in promoting up to four times more cellular
uptake of chimeras than their monovalent A10-3 aptamer-EEF2
shRNA chimera, therefore enhancing RNAi efficacy.
A recent study from Gilboa and his coworkers also success-
fully applied the anti-PSMA aptamer-siRNA chimera strategy to
the field of cancer immunotherapy (Pastor et al., 2010). The
A10 aptamer was employed to deliver anti-UpF2 and anti-Smg1
siRNAs to PSMA-expressing mouse tumor cells in culture. The sys-
temic administration (intravenous) of anti-PSMA aptamer-siRNA
chimeras also resulted in significant suppression of tumor growth
in subcutaneous and metastatic tumor animal model. Addition-
ally, upon high, long-term doses of the chimeras, most mice treated
completely rejected the tumor cells, which suggested aptamer-
mediated tumor-specific immunotherapy is a potential approach
for eradicating cancer.
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Currently, combination therapy for cancer using multiple treat-
ments (such as radiation and chemotherapy) has shown apparent
therapeutic benefits. However, escalated doses and non-targeting
cell killing may increase unwanted side effect and injury to
non-cancerous cells or tissues. Ionizing radiation (IR) causes
multiple types of cellular injury, which can be sensitized by
chemical or siRNA inhibition of DNA repair protein (Collis
et al., 2003; Ohnishi et al., 2006; Chalmers et al., 2007). In a
recent study, Lupold et al. described a prostate-targeted RNAi
agent selectively sensitized PSMA-positive cells to IR therapy (Ni
et al., 2011b). Through a high-throughput RNAi screen, sev-
eral novel siRNAs were identified against DNA-activated pro-
tein kinase, catalytic polypeptide (DNAPK) from siRNA library.
Using an established screening approach (McNamara et al.,
2006), a PSMA aptamer A10-3–DNAPK shRNA chimera was
generated (Figure 2B), which selectively reduced DNAPK gene
expression in PCa cells, xenografts, and human prostate tis-
sue (Ni et al., 2011b). Moreover, the aptamer-shRNA chimera
functioned as a selective sensitizing agent, as it dramatically
and specifically enhanced PSMA-positive tumor response to IR,
therefore reducing non-specific injury of IR to health cells or
tissues.
Most recently, an alternative cell-internalizing RNA aptamer
that binds to the human epidermal growth factor receptor 2
(HER2) was developed for delivering therapeutic siRNA to HER2-
expressing breast cancer cells (Thiel et al., 2012). HER2, one of
members in the epidermal growth factor receptor (EGFR) family, is
a key player in breast cancer (Sundaresan et al., 1999; Yarden, 2001;
Moasser, 2007). Compared to the cancer lacking HER2 expression,
HER2+ breast cancers is more aggressive and more likely to be
resistant to therapy (Higa et al., 2010; Davies and Hiscox, 2011).
In this study, the selected anti-HER2 aptamer was covalently fused
with Bcl2 siRNA to specifically induced gene silencing in HER2+-
cells, which sensitized these cells to chemotherapeutic cisplatin
(Thiel et al., 2012).
APTAMER-MEDIATED siRNA/shRNA-LOADED NANOCARRIER DELIVERY
Compared with traditional therapeutics, nanocarrier-based ther-
apeutics are capable of bearing various surface modifications
(e.g., targeting ligands, PEG) and accommodate multiple drugs
(e.g., RNAi therapeutics and small molecular drugs) simul-
taneously, thus altering drugs biodistribution, resistance, and
pharmacokinetics (PK). Nanocarriers can be decorated with
ligand-specific aptamers to achieve actively cell-type for deliv-
ery. Hence, aptamers can be used direct targeted delivery for a
variety of nanoparticles, including chemically synthesized poly-
mers, liposomes, Au-nanoparticles, quantum dots (QD), supra-
paramagnetic iron oxide nanoparticles (SPION), single wall car-
bon nanotubes (SWCNT; Levy-Nissenbaum et al., 2008; Thiel
and Giangrande, 2009, 2010). Moreover, the large surface areas
and the interior cavities of nanocarriers can provide excel-
lent platforms for conjugating multiple aptamers and stor-
ing large quantities of various therapeutic molecules, thereby
increasing loading capacity. Toward this end, RNAi-based ther-
apeutics have been loaded into various aptamer-functionalized
nanocarriers for targeted delivery of the siRNA (Burnett et al.,
2011).
Non-covalent aptamer-nanocarrier conjugates
As mentioned before, the interior volumes of nanoparticles can
be used to encapsulate large quantities of drug molecules. A
nanocomplex was formulated by incorporating both an anaplastic
lymphoma kinase (ALK) siRNA and an anti-CD30 RNA aptamer
(Mori et al., 2004; Zhang et al., 2009) onto polyethyleneimine
(PEI)-citrate nanocarriers via non-covalent interaction (Zhao
et al., 2011; Figure 2C). CD30 is a cell membrane protein of the
tumor necrosis factor receptor family that has been recognized as
a unique biomarker on many lymphomas of diverse origin and
as activation molecule on B- and T-cells (Duyster et al., 2001).
After directly mixing individual siRNAs and aptamers with PEI
to form an average ∼140 nm hydrodynamic diameter, the tar-
geted nanocomplexes specifically silenced ALK gene expression
and induced growth arrest and apoptosis in CD30-expressing
anaplastic large cell lymphoma (ALCL) cells (Zhao et al., 2011).
After entry of the aptamer-siRNA nanocomplexes into the tar-
geted cell, the therapeutic must escape from the endosome to
confer the siRNA function. With this in mind, Gao et al. (Bagalkot
and Gao, 2011) rationally designed a multifunctional nanopar-
ticle (PEI-coated quantum dot) system that is equipped with a
proton sponge effect to enhance endosomal escape (Figure 2C).
Additionally, the nanocomplex displays a large surface area for
high siRNA payload, exposed aptamer for specific targeting, and
fluorescence for imaging and qualification. Compared with the
conventional one-step incorporation of individual siRNA/shRNA
and aptamers onto a nanoparticle with random orientations and
conformations, this design requires a two-step process to graft
aptamer-siRNA chimeras onto nanoparticles. In this design, the
siRNAs with a thio-reactive terminal group are firstly adsorbed on
PEI-coated QD nanoparticles via non-covalent electrostatic inter-
action to reduce nanoparticle surface charge, thus avoiding some
non-specific electrostatic interactions between negatively charged
aptamers and nanoparticles surface. Next, PSMA aptamers with
a single thiol group are coupled to siRNAs via thiol-disulfide
exchange reaction to form aptamer-siRNA chimeras. Because
of the reduced positive charges on nanoparticles, their interac-
tion with aptamers is weakened, thus helping to retain aptamer
accessibility, flexibility, and binding affinity. The resulting PSMA
aptamer-targeting nanoparticles displayed selective gene silencing
and enabled 34% more silenced cells of the total cell population
over non-targeted nanoparticle-siRNA complexes (Bagalkot and
Gao, 2011).
Using a different strategy, Guo and coworkers fabricated an
anti-CD4 aptamer into a multifunctional nanostructure for tar-
geted delivery of siRNAs in a T-cell line expressing the human
CD4 receptor (Guo et al., 2005; Khaled et al., 2005). CD4 is a
glycoprotein expressed on the surface of certain subsets of T lym-
phocytes (Dalgleish et al., 1984; Hussey et al., 1988). The CD4
receptor can be endocytosed in T helper cells, internalizing itself
and any cargo to which it is bound (Pelchen-Matthews et al., 1991).
By using a soluble, recombinant CD4 antigen immobilized onto
sepharose beads, Kraus et al. (1998) successfully identified sev-
eral 2′-F-modified RNA aptamers, which blocked functional T-cell
responses. The packaging RNAs (pRNAs), derived from bacte-
riophage phi29 small RNAs, contain a 5′/3′ helical domain and
an intermolecular interaction domain. pRNA monomer can fold
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into a stable and unique secondary structure that serve as the
building blocks to form various nanostructures (e.g., dimer, timer,
hexamer, and larger arrays) in size from nanometers to microm-
eters through interlocking right- and left-hand loops (Guo, 2010;
Shu et al., 2011). When its 5′/3′ helical domains of pRNA are
substituted with an aptamer, siRNA, or other therapeutic mol-
ecules, the formation of pRNA-based nanostructure and their
therapeutic functions is not interfered. By taking advantage of
the self-assembling property of the pRNA, they have pioneered a
unique approach to assemble non-covalently siRNAs targeting sur-
vivin to an anti-CD4 aptamer-fused pRNA. The resulting chimeric
anti-CD4 aptamer-pRNA/pRNA-siRNA nanostructure (dimer of
25 nm in length) internalized specifically in CD4-expressing T-
cells and reduced viability of CD4+ but not CD4− T lymphocytes
in culture.
Covalent aptamer-nanoparticle conjugates
RNA aptamers can be chemically synthesized and modified with
different functional groups with relative ease, thus enabling
their covalent conjugation to the nanocarriers. Recently, a 5′-
NH2-modified PSMA aptamer was chemically synthesized and
covalently decorated on the surface of a polymer composed of
branched PEI grafted with PEG (PEI-PEG) for co-delivery of
shRNA and chemotherapy agents (Kim et al., 2010; Figure 2D).
In this design, PEG serves as a spacer to separate positively
charged PEI from aptamers, avoiding the interference with the
active folding of aptamers. The anthracycline class of anti-cancer
drugs (e.g., doxorubicin) was physically intercalated into the
double-stranded stem region of aptamers, and shRNA against
the anti-apoptotic factor Bcl-xL was complexed with positive
PEI polymer to form aptamer-conjugated nanoparticles. Their
results demonstrated that this combinatorial formulation syner-
gistically induced selective cell death of prostate cancer in com-
parison to a treatment in which the therapeutics simply are
mixed.
In a similar report, Yang et al. (2012) fabricated a biodegrad-
able nanoparticle using a poly(dl-lactic-co-glycolic acid) poly-
mer that encapsulated androgen receptor (AR) shRNA molecules.
After the AR shRNAs were loaded inside the particles, the surface
of the nanoparticles was then conjugated with the A10 anti-
PSMA aptamer for prostate cancer cell-specific targeting. A10-
conjugation enhanced cellular uptake of nanoparticles in both cell
culture and xenograft-based models. The efficacy of gene silenc-
ing was confirmed in PC-2/AR-derived xenografts in nude mice,
and two injections of the AR shRNA-loaded A10-nanoparticles
resulted in rapid tumor regressions.
In addition to siRNA/shRNA, miRNAs are another type of
small regulatory RNA that silences target messenger RNAs in a
sequence-specific manner MiRNAs are encoded in the genome and
transcribed from endogenous miRNA genes as primary transcripts
(pri-miRNAs), composed of∼65–70 nt stem-loop structures. The
mechanism of miRNA-mediated silencing is repression of target
mRNA translation accompanied by deadenylation and subsequent
degradation of the mRNA targets (Kurreck, 2009; Chiang et al.,
2010). MiR-15a and miR-16-1 have been identified as tumor sup-
pressor genes in prostate cancer (Bonci et al., 2008), and are
associated with the expression gene that promote the survival,
proliferation, and invasion in prostate cancer cells, including Bcl2,
CCND1, and WNT3 A (Sherr, 1996; Dhanasekaran et al., 2001;
Clevers, 2006). A truncated anti-PSMA aptamer (A10-3.2) was
used as a prostate cancer cell-specific ligand for microRNA-loaded
polyamidoamine (PAMAM) dendrimer delivery (Wu et al., 2011).
Using a PEG as a spacer, 3′-SH modified A10-3.2 was chemically
conjugated to the surface of PAMAM. The synthesized aptamer-
PEG-PAMAM dendrimer effectively delivered miR-15a and miR-
16-1 to prostate cancer cells overexpressing PSMA, resulting in
tumoricidal efficacy. The cell viability assay showed that IC50 value
of miRNA-loaded aptamer-PEG-PAMAM was approximately 4.7-
fold lower than of miRNA-loaded non-targeting-PEG-PAMAM
system, which was probably attributed to the targeting function of
aptamer.
CONCLUSION
In summary, RNA aptamers present a therapeutically valuable
approach to treating cancer and neurological disease via direct
interaction with cellular receptors or delivery of therapeuti-
cally valuable oligonucleotides. Nucleic acid-based aptamers offer
properties that rival or exceed small molecules and monoclonal
antibodies, including their high specificity, high affinity, relatively
small size, and controlled chemical synthesis (Sanghvi, 2011).
Compared to the antibody drugs, appropriate chemical modifica-
tions of therapeutic aptamers can be introduced in the solid-phase
synthesis to enhance not only their bio-stability but also the
pharmacodynamic (PD) and PK. In a very short span of time,
nine RNA or DNA aptamers have entered the clinical develop-
ment pipeline for treating a number of diseases (Ni et al., 2011a;
Burnett and Rossi, 2012). For example, Pegaptanib (Macugen), a
28-mer aptamer which was chemically modified with 2′-F-Py and
2′-OMe-Pu, became the first therapeutic aptamer approved for
the treatment of neovascular AMD (Ng et al., 2006). In addition,
this aptamer is currently being evaluated for use in cancer treat-
ment. Aptamers targeting cancer, described in this review, have
become one of the largest categories of aptamers and will con-
tinue to do so because of the potential for aptamers to recognize
cancer, but not healthy cells. Currently, a handful of aptamers
against β-secretase BACE1, amyloid fibril constituent Aβ and
PrP have been established for neurological disorders and are still
at pre-clinical stage. In addition, various aptamers raised from
a wide range of cancer targets are on their way into modern
medicine.
Apart from their utility as stand-alone therapeutics, cell-type
specific aptamers are readily employed as potential targeting lig-
ands for targeted therapy. Various aptamer-mediated drug deliv-
ery systems such as aptamer-siRNA/shRNA, aptamer-enzyme,
aptamer-antibody, aptamer-chemotherapy/phototherapy drugs,
and aptamer-nanoparticles have been established to achieve spe-
cific target recognition, therefore improving therapeutics index as
well as attenuating the overall toxicity of the drugs. The most com-
mon method used to harness the RNAi pathway for targeted gene
silencing is to transfect synthetic triggers (i.e., siRNAs, DsiRNAs,
or shRNAs) into cells, which is a key hurdle to the widespread
use of RNAi as a therapy. Although several pre-clinical studies
of aptamer-mediated siRNA targeting have been successful in the
animal models of cancer and neurodegenerative diseases, siRNA
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activity is often compromised when it is covalently fused to an
aptamer. Some design configurations only work well for a partic-
ular cell-type or molecular target. Therefore, while it is necessary
to develop guiding rules for designing active conjugates, it is also
important to validate the drug in a robust animal model. Addition-
ally, the uptake kinetics of the aptamer-drugs conjugates and the
mechanism how these RNAs escape from the endosome remain
unclear.
Currently, few aptamers are in clinical development due
to the cost and limited number of developed aptamers. RNA
aptamers are innately immunogenic and unstable; however, this
has been remedied by the incorporation of chemically modified
nucleotides. The high cost of large-scale, high-quality long RNA
aptamers with modified nucleotides limits the widespread use of
aptamers as therapeutics in clinically relevant populations. Never-
theless, the advantages and future prospects of aptamers outweigh
these limitations. Further developments in nucleotide synthesis
technology can overcome the high cost synthesis. Moreover, it is
estimated that the global market value for developing nucleic acid
aptamer therapeutics will continue growing in the coming years
as pharmaceutical industries are expected to invest in aptamer
development (Kang and Lee, 2012). Therefore, with continued
advances in SELEX technology and aptamer-based therapeutics,
new aptamers will be developed for the treatment and diagnoses
of cancer and neurodegenerative diseases. By incorporating nan-
otechnology, aptamers, and other therapeutics (siRNA/shRNA,
chemotherapy agents, etc.) can be assembled in one nanocarrier,
thus providing a multifunctional therapeutic nanoscale device. For
these reasons, we anticipate that aptamers offer a promising new
class of medicine in the near future.
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